Proteasome inhibition: a new therapeutic strategy to cancer treatment.
about
Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents.MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κBMulti-analyte network markers for tumor prognosis.The role of proteasome inhibition in nonsmall cell lung cancerTargeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control.Morphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome InhibitorsThe Role of Cathelicidin LL-37 in Cancer Development.Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.Subcellular distribution and dynamics of active proteasome complexes unraveled by a workflow combining in vivo complex cross-linking and quantitative proteomics.Proteasome inhibitor MG-132 induces MCPIP1 expressionNovel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell linesThe autophagic paradox in cancer therapy.Proteomics to study the diversity and dynamics of proteasome complexes: from fundamentals to the clinic.Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.Therapeutic targeting of cancer cell cycle using proteasome inhibitorsRelationship between the proteasomal system and autophagy.Modulation of protein quality control systems by food phytochemicals.Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts.Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells.Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib-treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms.Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.Inhibition of protein degradation induces apoptosis through a microtubule-associated protein 1 light chain 3-mediated activation of caspase-8 at intracellular membranes.Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells.Novel green synthesis of gold nanoparticles using Citrullus lanatus rind and investigation of proteasome inhibitory activity, antibacterial, and antioxidant potentialCombined 3D-QSAR, molecular docking and molecular dynamics study on derivatives of peptide epoxyketone and tyropeptin-boronic acid as inhibitors against the β5 subunit of human 20S proteasome.Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
P2860
Q30275189-029DA03F-FD24-4240-8A77-7EA28A243CD6Q34036615-B2E42F59-289E-4F54-B1F6-4A20A6B7FFE7Q34038263-3DCF718C-7B50-45F0-9B72-BE2FA607E8BAQ34541470-7B571B3E-6CF8-43CC-A031-F18EAA262EA2Q35001441-9469CC95-530A-4ABE-BD79-D1F7EFCD0271Q35762274-86E57FC4-8629-47B4-943F-72BF2ABD6184Q35770195-4773978E-06C3-4FCE-AF01-88E201080A3CQ35812372-D6FAEECD-67CF-42BF-BC1E-85F2F1F55E37Q36465085-D754B00E-4535-474D-B39A-209A9648DE75Q36558030-316E5D3B-60B5-47F5-A301-6CC9A463BE05Q36666357-C4EA9ECA-AC4F-49B7-ADC6-0D2B6D20A821Q37250219-989CD7F0-20DD-4DF2-916C-3DFBDADD5ACBQ37298880-80074B8B-1458-42A2-82B6-745A504D7D8EQ37377197-CF4EC3E2-85FD-4FA7-85C0-38A5DE4EF2B4Q37414942-BFD841DD-87E6-4BAD-8779-62A8C7F6647CQ37902052-19D4CF3A-AB92-42A3-9688-8526B6DC8DEAQ37912201-A8A64C56-244B-40C9-AC3A-DC705FA115C7Q37951013-69192BEC-4353-4568-AAEB-D1A481C06ABDQ38069898-9601A033-128D-492A-BA00-E52EF6C452D5Q38103557-70308E24-E705-40EB-AC78-A57436A538D1Q38109158-4BFBBF16-335E-4205-A2B5-46FAC2C70A79Q38111684-3919F914-F5E8-497A-B471-BEC1CE34FB8CQ38152513-263EC27D-A52F-4A5A-86DB-9CA6FFD0C0ACQ38962397-44A12601-3E8B-453C-AB7A-C211A34130CCQ38973261-27B840E3-4307-4D57-8E4C-283E661AD2FFQ38999358-94BFE810-7E4C-4566-AEA2-14859387D374Q39247959-6D20B9D4-005B-4003-A9B9-B8B6AF88B907Q39369141-088C6A79-6F88-4C39-BEC7-E3543DCDDC6BQ39510395-0A15D241-0C0E-433B-ABAB-063ED0CD755FQ39532979-EE00B58B-C88F-4646-9A4B-B21BFFD24FF7Q40211696-035DB210-1B4E-4E28-9103-DC7FEC2B5B67Q41982178-FE98356D-39AF-4A54-B5B4-0BBD8665D9DEQ42034676-026D362F-992E-43AF-9985-92C43854B8E3Q42751397-8B59C7EA-C9F5-427D-8F03-082779C0FE40Q47446573-7C2087CB-B3DC-4B9A-A59D-402E730E5B36Q47955863-BC0C1B39-56BE-4694-8009-DF87D79A0BB9
P2860
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
@en
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
@nl
type
label
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
@en
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
@nl
prefLabel
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
@en
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
@nl
P2093
P1433
P1476
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
@en
P2093
Chi Hin Cho
Chung Wa Lee
Daiming Fan
Joseph Jao Yiu Sung
Kaichun Wu
William Ka Kei Wu
P356
10.1016/J.CANLET.2009.12.002
P407
P577
2010-02-04T00:00:00Z